Side-by-side comparison of AI visibility scores, market position, and capabilities
Boston biopharma AI platform automating competitive landscape, regulatory intelligence, and clinical research for DayOne and ZS Associates; YC $3.1M Pags/Splash seed competing with Citeline and Evaluate for AI-powered pharma knowledge work.
Maven Bio is a Boston, Massachusetts-based AI platform for biopharma knowledge work — backed by Y Combinator with $3.1 million in seed funding led by Pags Group, Splash Capital, and NVO Group with YC participation, following a $500,000 pre-seed from YC in September 2023 — providing biopharma companies, consultancies, and investors with domain-specific AI modules built on curated biopharma industry data that automate the research, analysis, and synthesis tasks that pharmaceutical knowledge workers perform manually. Founded in 2023 by Michael Brady and Arjun Murthy and operating with an 8-person team in Boston, Maven Bio serves customers including DayOne and ZS Associates (the global biopharma consulting firm) with a platform that converts biopharma questions into decisions faster through AI-powered access to curated drug development, clinical, and regulatory knowledge.
Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.